Abstract
Apoptotic pathways controlled by the Rel/NF-κB family of transcription factors may regulate the response of cells to DNA damage. Here, we have examined the NF-κB status of several prostate tumor cell lines. In the androgen-independent prostate tumor cells PC-3 and DU-145, the DNA-binding activity of NF-κB was constitutively activated and IκB-α levels were decreased. In contrast, the androgen-sensitive prostate tumor cell line LNCaP had low levels of NF-κB which were upregulated following exposure to cytokines or DNA damage. The activity of the IκB-α kinase, IKKα, which mediates NF-κB activation, was also measured. In PC-3 cells, IKKα activity was constitutively active, whereas LNCaP cells had minimal IKKα activity that was activated by cytokines. The anti-inflammatory agent ibuprofen inhibited the constitutive activation of NF-κB and IKKα in PC-3 and DU-145 cells, and blocked stimulated activation of NF-κB in LNCaP cells. However, ibuprofen did not directly inhibit IκB-α kinase. The results demonstrate that NF-κB is constitutively activated in the hormone-insensitive prostate tumor cell lines PC-3 and DU-145, but not in the hormone responsive LNCaP cell line. The constitutive activation of NF-κB in prostate tumor cells may increase expression of anti-apoptotic proteins, thereby decreasing the effectiveness of anti-tumor therapy and contributing to the development of the malignant phenotype.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Apakama I, Robinson M, Walter N, Charlton R, Royds J, Fuller C, Neal D and Hamdy F. . 1996 Br. J. Cancer 8: 1258–1262.
Baeuerle PA and Baltimore D. . 1996 Cell 87: 13–20.
Basu S, Rosenzweig KE, Youmell MY and Price BD. . 1998 Biochem. Biophys. Res. Comm. 247: 79–83.
Beg AA and Baltimore D. . 1996 Science 274: 782–784.
Cohen L, Henzel WJ and Baeuerle PA. . 1998 Nature 395: 292–296.
de Moissac D, Mustapha S, Greenberg AH and Kirshenbaum LA. . 1998 J. Biol. Chem. 273: 23946–23951.
DeWitt D and Smith WL. . 1995 Cell 83: 345–348.
Kopp E and Ghosh S. . 1994 Science 265: 956–959.
Krappmann D, Emmerich F, Kordes U, Scharschmidt E, Dorken B and Scheidereit C. . 1999 Oncogene 18: 943–953.
Laska EM, Sunshine A, Marrero I, Olson N, Siegel C and McCormick N. . 1986 Clin. Pharm. Ther. 40: 1–7.
Latchman DS. . 1999 J. Cell. Physiol. 179: 126–133.
Lee FS, Peters RT, Dang LC and Maniatis T. . 1998 Proc. Natl. Acad. Sci. USA 95: 9319–9324.
Ling L, Cao Z and Goeddel DV. . 1998 Proc. Natl. Acad. Sci. USA 95: 3792–3797.
Mercurio F, Zhu H, Murray BW, Shevchenko A, Bennett BL, Li JW, Young DB, Barbossa M, Mann M, Manning A and Rao A. . 1997 Science 278: 860–866.
Miyamato S and Verma IM. . 1995 Adv. Cancer Res. 66: 255–292.
Nakajima Y, DelliPizzi AM, Mallouh C and Ferreri R. . 1996 Prostate 29: 296–302.
Nakshatri H, Bhat-Nakshatri P, Martin DA, Goulet RJ and Sledge GW. . 1997 Mol. Cell Biol. 17: 3629–3639.
Palayoor ST, Bump EA, Calderwood SK, Bartol S and Coleman CN. . 1998 Clin. Cancer Res. 4: 763–771.
Palvimo JJ, Reinikainen P, Ikonen T, Kallio PJ, Moilanen A and Janne OA. . 1996 J. Biol. Chem. 271: 24151–24156.
Perez P, Lira SA and Bravo R. . 1995 Mol. Cell Biol. 15: 3523–3530.
Soncin F and Calderwood SK. . 1996 Biochem. Biophys. Res. Comm. 229: 479–484.
Sun S-C, Ganchi PA, Ballard DW and Greene WC. . 1993 Science 259: 1912–1915.
Supakar PC, Jung MH, Song CS, Chatterjee B and Roy A. . 1995 J. Biol. Chem. 270: 837–842.
Teicher BA, Bump EA, Palayoor S, Northey D and Coleman CN. . 1996 Rad. Oncol. Invest. 4: 221–230.
Tilley WD, Wilson CM, Marcelli M and McPhaul MJ. . 1990 Cancer Res. 50: 5382–5386.
Traenckner EB, Pahl HL, Henkel T, Schmidt KN, Wilk S and Baeuerle PA. . 1995 EMBO J. 14: 2876–2883.
Wang C-Y, Mayo MW and Baldwin AS. . 1996 Science 274: 784–787.
Wang C-Y, Mayo MW, Korneluk RG, Goeddel DV and Baldwin AS. . 1998 Science 281: 1680–1683.
Wu MX, Ao Z, Prasad KVS, Wu R and Schlossman SF. . 1998 Science 281: 998–1001.
Yin MJ, Yamamoto Y and Gaynor RB. . 1998 Nature 396: 77–80.
Zandi E, Chen Y and Karin M. . 1998 Science 281: 1360–1363.
Acknowledgements
Supported by grants from the National Institutes of Health (CA64585), US Army (DOD Prostate Cancer Grant) and by funds from the AJCRT Foundation.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Palayoor, S., Youmell, M., Calderwood, S. et al. Constitutive activation of IκB kinase α and NF-κB in prostate cancer cells is inhibited by ibuprofen. Oncogene 18, 7389–7394 (1999). https://doi.org/10.1038/sj.onc.1203160
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1203160
Keywords
This article is cited by
-
ROC1 promotes the malignant progression of bladder cancer by regulating p-IκBα/NF-κB signaling
Journal of Experimental & Clinical Cancer Research (2021)
-
Protective role of exogenous recombinant peroxiredoxin 6 under ischemia-reperfusion injury of kidney
Cell and Tissue Research (2019)
-
Aqueous extract of Sapindus mukorossi induced cell death of A549 cells and exhibited antitumor property in vivo
Scientific Reports (2018)
-
Radiosensitizing effect of ellagic acid on growth of Hepatocellular carcinoma cells: an in vitro study
Scientific Reports (2017)
-
N-Myc-Interacting Protein Negatively Regulates TNF-α-Induced NF-κB Transcriptional Activity by Sequestering NF-κB/p65 in the Cytoplasm
Scientific Reports (2017)